Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Accumulated Expenses (2023 - 2025)

Beta Bionics (BBNX) has disclosed Accumulated Expenses for 3 consecutive years, with $22.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 41.72% to $22.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.4 million through Dec 2025, up 41.72% year-over-year, with the annual reading at $22.4 million for FY2025, 41.72% up from the prior year.
  • Accumulated Expenses hit $22.4 million in Q4 2025 for Beta Bionics, up from $17.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $22.4 million in Q4 2025 to a low of $8.1 million in Q4 2023.
  • Historically, Accumulated Expenses has averaged $14.7 million across 3 years, with a median of $14.6 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 94.73% in 2024 and later skyrocketed 41.72% in 2025.
  • Year by year, Accumulated Expenses stood at $8.1 million in 2023, then surged by 94.73% to $15.8 million in 2024, then skyrocketed by 41.72% to $22.4 million in 2025.
  • Business Quant data shows Accumulated Expenses for BBNX at $22.4 million in Q4 2025, $17.6 million in Q3 2025, and $13.4 million in Q2 2025.